MedPath

Palliation of Dyspnea With Mouth Piece Ventilation

Not Applicable
Terminated
Conditions
Dyspnea
Interventions
Device: Trilogy 100 ® (Philips Respironics)
Registration Number
NCT03012737
Lead Sponsor
Tampere University Hospital
Brief Summary

An uncontrolled feasibility study on using mouth piece ventilation in palliation of dyspnea in subjects with incurable advanced disease. Subjects are recruited from a local Hospice and from oncology ward. The main outcomes are the compliance of the subjects with the treatment and alleviation of dyspnea during the treatment period.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • at least moderate dyspnea (NRS = Numeric Rating Scale ≥ 4)
  • incurable advanced disease
  • able to understand the study and to give informed consent
  • would not gain from intensive care or resuscitation according to the treating physician
Exclusion Criteria
  • unable to participate and use MPV due to e.g. delirium or lack of co-operation
  • the cause of the dyspnea can be succesfully treated
  • unable to give informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
MPV armTrilogy 100 ® (Philips Respironics)Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
Primary Outcome Measures
NameTimeMethod
Change in dyspnea after initial use of MPV5 - 60 min
Secondary Outcome Measures
NameTimeMethod
Change in dyspnea after 24 hours of using MPV24 hours
Proportion of subjects gaining from MPV24 hours
Proportion of subjects having side-effects or not being compliant with MPV24 hours
Proportion of subjects willing to continue on MPV after the intervention24 hours

Trial Locations

Locations (2)

Dpt of oncology, Tampere University Hospital

🇫🇮

Tampere, Finland

Pirkanmaa Hospice

🇫🇮

Tampere, Finland

© Copyright 2025. All Rights Reserved by MedPath